Comparative Analysis Of Dexmedetomidine And Dexamethasone As An Adjuvant To 0.5%Ropivacaine On Onset Of Ultrasound Guided Supraclavicular Brachial Plexus Block In Patients Undergoing Upper Limb Surgeries

Trial statusRecruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
Age18-70
SponsorSahiwal medical college sahiwal

About this trial

To compare the efficacy of dexmedetomidine and dexamethasone as an adjuvant to 0.5%ropivacaine on onset of ultrasound guided supraclavicular brachial plexus block in patients undergoing upper limb surgeries.

Ropivacaine hydrochloride, a long acting local anesthetic, is commonly used for supraclavicular block owing to its favorable safety profile especially in terms of minimal cardiotoxicity and less motor block. Dexmedetomidine, a highly selective alpha-2 adrenergic agonist, enhances the quality of supraclavicular block by providing sedation and analgesia while potentially prolonging the duration of block through hyperpolarization of nerve fibers. While, Dexamethasone, a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties, prolongs duration of analgesia by reducing perineural inflammation and inhibiting nociceptive signal transmission. Supraclavicular brachial plexus block offers dense anesthesia for surgical procedures at or distal to the elbow with relatively high success rate, once described as "spinal of the arm". Moreover, supraclavicular brachial plexus block is an excellent alternative to general anesthesia in upper limb surgeries.

Eligibility criteria

Qualifiers

Patients scheduled for upper limb surgery below mid-humerus level

Patients aged 18 to 70 years

Patients with ASA class I, II and III

Male and non-pregnant females

Disqualifiers

Patients refusal

Patients with pre-existing peripheral neuropathy of the upper limb

Patients with the Infection at block site

Patients with history of ischemic heart disease

Trial design

Treatments tested in this trial

  • Ropivacaine + Dexmedetomidine
  • Ropivacaine + dexamethasone

Treatment groups

66 Participants
are divided into 2 treatment groups

Locations

1
Sahiwal Medical College, Sahiwal57000, SāhīwālPunjab Province, Pakistan

Sponsors and collaborators

Sahiwal medical college sahiwal

Lead sponsor